Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Apr;2(4):332-40.
doi: 10.1158/2326-6066.CIR-13-0136. Epub 2014 Jan 27.

Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome

Bridget Charbonneau  1 Kirsten B MoysichKimberly R KalliAnn L ObergRobert A VierkantZachary C FogartyMatthew S BlockMatthew J MaurerKrista M GoergenBrooke L FridleyJulie M CunninghamDavid N RiderClaudia PrestonLynn C HartmannKate LawrensonChen WangJonathan TyrerHonglin SongAnna deFazioSharon E JohnattyJennifer A DohertyCatherine M PhelanThomas A SellersStarr M RamirezAllison F VitonisKathryn L TerryDavid Van Den BergMalcolm C PikeAnna H WuAndrew BerchuckAleksandra Gentry-MaharajSusan J RamusBrenda DiergaardeHoward ShenAllan JensenJanusz MenkiszakCezary CybulskiJan LubiłskiArgyrios ZiogasJoseph H RothsteinValerie McGuireWeiva SiehJenny LesterChristine WalshIgnace VergoteSandrina LambrechtsEvelyn DespierreMontserrat Garcia-ClosasHannah YangLouise A BrintonBeata SpiewankiewiczIwona K RzepeckaAgnieszka Dansonka-MieszkowskaPetra SeiboldAnja RudolphLisa E PaddockIrene OrlowLene LundvallSara H OlsonClaus K HogdallIra SchwaabAndreas du BoisPhilipp HarterJames M FlanaganRobert BrownJames PaulArif B EkiciMatthias W BeckmannAlexander HeinDiana EcclesGalina LurieLaura E HaysYukie T BeanTanja PejovicMarc T GoodmanIan CampbellPeter A FaschingGottfried KonecnyStanley B KayeFlorian HeitzEstrid HogdallElisa V BanderaJenny Chang-ClaudeJolanta KupryjanczykNicolas WentzensenDiether LambrechtsBeth Y KarlanAlice S WhittemoreHoda Anton CulverJacek GronwaldDouglas A LevineSusanne K KjaerUsha MenonJoellen M SchildkrautCeleste Leigh PearceDaniel W CramerMary Anne RossingGeorgia Chenevix-TrenchAOCS groupACSPaul D P PharoahSimon A GaytherRoberta B NessKunle OdunsiLara E SuchestonKeith L KnutsonEllen L Goode
Affiliations

Large-scale evaluation of common variation in regulatory T cell-related genes and ovarian cancer outcome

Bridget Charbonneau et al. Cancer Immunol Res. 2014 Apr.

Abstract

The presence of regulatory T cells (Treg) in solid tumors is known to play a role in patient survival in ovarian cancer and other malignancies. We assessed inherited genetic variations via 749 tag single-nucleotide polymorphisms (SNP) in 25 Treg-associated genes (CD28, CTLA4, FOXP3, IDO1, IL10, IL10RA, IL15, 1L17RA, IL23A, IL23R, IL2RA, IL6, IL6R, IL8, LGALS1, LGALS9, MAP3K8, STAT5A, STAT5B, TGFB1, TGFB2, TGFB3, TGFBR1, TGRBR2, and TGFBR3) in relation to ovarian cancer survival. We analyzed genotype and overall survival in 10,084 women with invasive epithelial ovarian cancer, including 5,248 high-grade serous, 1,452 endometrioid, 795 clear cell, and 661 mucinous carcinoma cases of European descent across 28 studies from the Ovarian Cancer Association Consortium (OCAC). The strongest associations were found for endometrioid carcinoma and IL2RA SNPs rs11256497 [HR, 1.42; 95% confidence interval (CI), 1.22-1.64; P = 5.7 × 10(-6)], rs791587 (HR, 1.36; 95% CI, 1.17-1.57; P = 6.2 × 10(-5)), rs2476491 (HR, = 1.40; 95% CI, 1.19-1.64; P = 5.6 × 10(-5)), and rs10795763 (HR, 1.35; 95% CI, 1.17-1.57; P = 7.9 × 10(-5)), and for clear cell carcinoma and CTLA4 SNP rs231775 (HR, 0.67; 95% CI, 0.54-0.82; P = 9.3 × 10(-5)) after adjustment for age, study site, population stratification, stage, grade, and oral contraceptive use. The rs231775 allele associated with improved survival in our study also results in an amino acid change in CTLA4 and previously has been reported to be associated with autoimmune conditions. Thus, we found evidence that SNPs in genes related to Tregs seem to play a role in ovarian cancer survival, particularly in patients with clear cell and endometrioid epithelial ovarian cancer.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: B Charbonneau was an employee of Mayo Clinic at the time this manuscript was drafted and is currently an employee of and owns stock in Eli Lilly and Company.

Figures

Figure 1
Figure 1
Kaplan–Meier curves accounting for left-truncation for the most statistically significantly associated SNPs and overall survival in women with (A) endometrioid EOC with rs11256497 genotype [GG(N=582), AG(N=670), and AA(N=200)]; (B) clear cell EOC with rs231775 genotype [AA(N=313), AG(N=379), and GG(N=103)]; (C) high-grade serous EOC with rs6770038 genotype [GG(N=3, 484), AG(N=1,604), and AA(N=160)]; (D) mucinous EOC with rs4658265 genotype [GG(N=305), AG(N=295), and AA(N=61)]; and (E) any invasive EOC with rs4522809 genotype [AA(N=2,782), AG(N=5,069), and GG(N=2,232)].
Figure 2
Figure 2
SNPs most statistically significantly associated with overall survival in endometrioid and clear cell EOC. Association p-values (−log10(p-value)) using LocusZoom (30) of all SNPs in (A) IL2RA for endometrioid (rs11256497 represented by purple circle), (B) CTLA4 for clear cell (rs231775 represented by purple triangle), (C) TGFBR2 for high-grade serous (rs6770038 represented by purple circle), (D) TGFBR3 for mucinous (rs4658265 represented by purple circle), and (E) TGFBR2 for all invasive EOC (rs4522809 represented by purple circle). Annotation key: ▲ - framestop or splice; ▼ - NonSynonymous; ■ - Synonymous or UTR; ● – no; × - conserved in placental mammals
Figure 3
Figure 3
IL2RA mRNA expression (normalized and log10 transformed) by rs11256497 genotype in endometrioid EOC tumors. Two different Agilent IL2RA probes are presented A) A_23_P237288 and B) A_24_P230563. Two-tailed, unpaired t test p-value is reported.

Similar articles

  • Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.
    Sieh W, Köbel M, Longacre TA, Bowtell DD, deFazio A, Goodman MT, Høgdall E, Deen S, Wentzensen N, Moysich KB, Brenton JD, Clarke BA, Menon U, Gilks CB, Kim A, Madore J, Fereday S, George J, Galletta L, Lurie G, Wilkens LR, Carney ME, Thompson PJ, Matsuno RK, Kjær SK, Jensen A, Høgdall C, Kalli KR, Fridley BL, Keeney GL, Vierkant RA, Cunningham JM, Brinton LA, Yang HP, Sherman ME, García-Closas M, Lissowska J, Odunsi K, Morrison C, Lele S, Bshara W, Sucheston L, Jimenez-Linan M, Driver K, Alsop J, Mack M, McGuire V, Rothstein JH, Rosen BP, Bernardini MQ, Mackay H, Oza A, Wozniak EL, Benjamin E, Gentry-Maharaj A, Gayther SA, Tinker AV, Prentice LM, Chow C, Anglesio MS, Johnatty SE, Chenevix-Trench G, Whittemore AS, Pharoah PD, Goode EL, Huntsman DG, Ramus SJ. Sieh W, et al. Lancet Oncol. 2013 Aug;14(9):853-62. doi: 10.1016/S1470-2045(13)70253-5. Epub 2013 Jul 9. Lancet Oncol. 2013. PMID: 23845225 Free PMC article.
  • Variation in NF-κB signaling pathways and survival in invasive epithelial ovarian cancer.
    Block MS, Charbonneau B, Vierkant RA, Fogarty Z, Bamlet WR, Pharoah PD; Georgia Chenevix-Trench; for AOCS; /ACS Group; Rossing MA, Cramer D, Pearce CL, Schildkraut J, Menon U, Kjaer SK, Levine DA, Gronwald J, Culver HA, Whittemore AS, Karlan BY, Lambrechts D, Wentzensen N, Kupryjanczyk J, Chang-Claude J, Bandera EV, Hogdall E, Heitz F, Kaye SB, Fasching PA, Campbell I, Goodman MT, Pejovic T, Bean YT, Hays LE, Lurie G, Eccles D, Hein A, Beckmann MW, Ekici AB, Paul J, Brown R, Flanagan JM, Harter P, du Bois A, Schwaab I, Hogdall CK, Lundvall L, Olson SH, Orlow I, Paddock LE, Rudolph A, Eilber U, Dansonka-Mieszkowska A, Rzepecka IK, Ziolkowska-Seta I, Brinton LA, Yang H, Garcia-Closas M, Despierre E, Lambrechts S, Vergote I, Walsh CS, Lester J, Sieh W, McGuire V, Rothstein JH, Ziogas A, Lubiński J, Cybulski C, Menkiszak J, Jensen A, Gayther SA, Ramus SJ, Gentry-Maharaj A, Berchuck A, Wu AH, Pike MC, Van Den Berg D, Terry KL, Vitonis AF, Ramirez SM, Rider DN, Knutson KL, Sellers TA, Phelan CM, Doherty JA, Johnatty SE, deFazio A, Song H, Tyrer J, Kalli KR, Fridley BL, Cunningham JM, Goode EL. Block MS, et al. Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1421-7. doi: 10.1158/1055-9965.EPI-13-0962. Epub 2014 Apr 16. Cancer Epidemiol Biomarkers Prev. 2014. PMID: 24740199 Free PMC article.
  • Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis.
    Yarmolinsky J, Relton CL, Lophatananon A, Muir K, Menon U, Gentry-Maharaj A, Walther A, Zheng J, Fasching P, Zheng W, Yin Ling W, Park SK, Kim BG, Choi JY, Park B, Davey Smith G, Martin RM, Lewis SJ. Yarmolinsky J, et al. PLoS Med. 2019 Aug 7;16(8):e1002893. doi: 10.1371/journal.pmed.1002893. eCollection 2019 Aug. PLoS Med. 2019. PMID: 31390370 Free PMC article.
  • Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
    Mackay HJ, Brady MF, Oza AM, Reuss A, Pujade-Lauraine E, Swart AM, Siddiqui N, Colombo N, Bookman MA, Pfisterer J, du Bois A; Gynecologic Cancer InterGroup. Mackay HJ, et al. Int J Gynecol Cancer. 2010 Aug;20(6):945-52. doi: 10.1111/IGC.0b013e3181dd0110. Int J Gynecol Cancer. 2010. PMID: 20683400 Review.
  • Uptake and Outcomes of Neoadjuvant Chemotherapy Among US Patients With Less Common Epithelial Ovarian Carcinomas.
    Matsuo K, Matsuzaki S, Maeda M, Rau AR, Yoshihara K, Tamura R, Shimada M, Machida H, Mikami M, Klar M, Roman LD, Wright JD, Sood AK, Gershenson DM. Matsuo K, et al. JAMA Netw Open. 2023 Jun 1;6(6):e2318602. doi: 10.1001/jamanetworkopen.2023.18602. JAMA Netw Open. 2023. PMID: 37326992 Free PMC article.

Cited by

References

    1. Zhao X, Wei YQ, Peng ZL. Induction of T cell responses against autologous ovarian tumors with whole tumor cell lysate-pulsed dendritic cells. Immunol Invest. 2001;30:33–45. - PubMed
    1. Hwang W-T, Adams SF, Tahirovic E, Hagemann IS, Coukos G. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis. Gynecol Oncol. 2012;124:192–198. - PMC - PubMed
    1. Gooden MJ, de Bock GH, Leffers N, Daemen T, Nijman HW. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105:93–103. - PMC - PubMed
    1. Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol. 2010;117:366–372. - PubMed
    1. Bilate AM, Lafaille JJ. Induced CD4+Foxp3+ regulatory T cells in immune tolerance. Annu Rev Immunol. 2012;30:733–758. - PubMed

Publication types

Substances

Grants and funding